Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mersana Therapeutics Inc.

6.07
+0.10001.68%
Volume:39.56K
Turnover:241.76K
Market Cap:30.26M
PE:-0.40
High:6.31
Open:6.01
Low:6.01
Close:5.97
52wk High:70.75
52wk Low:5.85
Shares:4.99M
Float Shares:3.75M
Volume Ratio:0.60
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-15.0059
EPS(LYR):-14.1162
ROE:-505.14%
ROA:-30.90%
PB:-0.98
PE(LYR):-0.43

Loading ...

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

GlobeNewswire
·
Apr 01

Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates

Simply Wall St.
·
Mar 06

Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts

Simply Wall St.
·
Mar 05

Truist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)

TIPRANKS
·
Mar 04

Mersana Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
Mar 04

Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com
·
Mar 04

Mersana Therapeutics’ Viability in Question Amidst Persistent Financial Losses and Funding Challenges

TIPRANKS
·
Mar 04

Q4 2024 Mersana Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
Mar 04

Mersana Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 04

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
Mar 03

Mersana Therapeutics Q4 EPS $(0.11) Beats $(0.15) Estimate, Sales $16.36M Beat $7.71M Estimate

Benzinga
·
Mar 03

BRIEF-Mersana Therapeutics Q4 EPS USD -0.11

Reuters
·
Mar 03

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
Mar 03

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 03

BRIEF-Mersana Therapeutics Receives Nasdaq Non-Compliance Notice

Reuters
·
Mar 01

Mersana Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
Feb 28

Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

GlobeNewswire
·
Feb 25

Mersana Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
Feb 24